HLS Therapeutics Company Description

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products for the treatment of psychiatric disorders, central nervous system, and cardiovascular disease in Canada, the United States, and internationally.

The company’s lead products include Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.

It also distributes MyCare psychiatry lab assays; and MyCare Insite, a point-of-care device to measure patient drug levels.

In addition, the company holds royalty interest in Takeda’s Obizur, which is a porcine recombinant Factor VIII for acquired Hemophilia A.

HLS Therapeutics Inc. is headquartered in Etobicoke, Canada.